Jennifer E Stark

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5247342/publications.pdf

Version: 2024-02-01

		1163117	1125743
19	166	8	13
papers	citations	h-index	g-index
20	20	20	192
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Pantoprazole-Induced Thrombocytopenia. Annals of Pharmacotherapy, 2006, 40, 758-761.	1.9	41
2	Venous Thromboembolic Prophylaxis in Hospitalized Medical Patients. Annals of Pharmacotherapy, 2004, 38, 36-40.	1.9	30
3	Olanzapine-Associated Neuroleptic Malignant Syndrome. Pharmacotherapy, 2006, 26, 1180-1182.	2.6	14
4	Evaluating the impact of a pre-rotation workshop on student preparation for clinical advanced pharmacy practice experiences. Pharmacy Practice, 2008, 6, 219-23.	1.5	13
5	Impact of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) on Food Content During Esophagogastroduodenoscopy (EGD). Annals of Pharmacotherapy, 2022, 56, 922-926.	1.9	13
6	Stevens-Johnson Syndrome Associated With Furosemide. Journal of Pharmacy Practice, 2010, 23, 367-370.	1.0	12
7	Treatment of Chronic Hepatitis C Virus Infection With Crushed Ledipasvir/Sofosbuvir Administered via a Percutaneous Endoscopic Gastrostomy Tube. Journal of Pharmacy Practice, 2018, 31, 522-524.	1.0	11
8	Hyperchloremic, normal anion-gap, metabolic acidosis due to topiramate. American Journal of Health-System Pharmacy, 2008, 65, 1430-1434.	1.0	9
9	Potential for a Significant Interaction Between Clopidogrel and Dasabuvir. Clinical Infectious Diseases, 2015, 61, 134-135.	5.8	5
10	Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. American Journal of Health-System Pharmacy, 2017, 74, 1541-1544.	1.0	5
11	A Pharmacist-Initiated Method to Improve Venous Thromboembolic Prophylaxis Rates in Medically Ill Patients. Journal of Pharmacy Practice, 2006, 19, 275-279.	1.0	3
12	Pharmacotherapy for Heart Failure with Left Ventricular Dysfunction: Beyond Angiotensin-Converting Enzyme Inhibitors and Î ² -Blockers. Pharmacotherapy, 2008, 28, 920-931.	2.6	3
13	Multidisciplinary Approach to Improve Venous Thromboembolism Risk Assessment and Prophylaxis Rates in Hospitalized Patients. Journal of Pharmacy Technology, 2012, 28, 171-178.	1.0	1
14	Provider and Nursing Perceptions and Practices. Journal of Intensive Care Medicine, 2016, 31, 493-493.	2.8	1
15	Identifying Missed Opportunities for the Pneumococcal Conjugate Vaccine (PCV13). Journal of Pharmacy Technology, 2018, 34, 24-27.	1.0	1
16	A facility mandate for pharmacist assessment improves venous thromboembolism outcomes. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 274-280.	1.0	1
17	Deinduction of Pâ€glycoprotein resulting in delayed viral response during hepatitis C treatment. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1465-1468.	1.5	1
18	Implementation of a novel learning experience in scientific writing, publishing, and peer review into a First Year Pharmacy Practice Residency. Journal of the American Pharmacists Association: JAPhA, 2021, , .	1.5	1

#	Article	lF	CITATIONS
19	Prophylaxis for Thromboembolism Pilot Study: Comments to the Editor. American Journal of Medicine, 2007, 120, e15.	1.5	O